ID: ALA5207947

Max Phase: Preclinical

Molecular Formula: C215H298N48O58S7

Molecular Weight: 4707.50

Associated Items:

Representations

Canonical SMILES:  CCCC[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CSCCC(=O)N3CN(CN(C3)C(=O)CCSC[C@@H](C(=O)N[C@@H](C)C(N)=O)NC1=O)C(=O)CCSC[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](CCCCNC(=O)CCc1cn(CCOCCOCCOCCOCCOCCC(=O)N[C@H]3CSCCC(=O)N4CN5CN(C4)C(=O)CCSC[C@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc4cccc6ccccc46)NC(=O)[C@@H]4CCCN4C3=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N3CCC[C@H]3C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@H](C(N)=O)CSCCC5=O)nn1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N2

Standard InChI:  InChI=1S/C215H298N48O58S7/c1-10-11-39-142-187(290)245-160(199(302)224-122(2)183(216)286)112-325-90-65-174(274)254-118-252-119-255(120-254)176(276)67-92-327-114-162(202(305)233-147(94-126-31-13-12-14-32-126)190(293)225-123(3)185(288)241-155(103-181(284)285)209(312)259-72-27-46-166(259)205(308)237-148(191(294)229-142)95-127-49-54-134(267)55-50-127)246-192(295)149(96-128-51-56-135(268)57-52-128)238-204(307)165-45-26-71-258(165)208(311)146(232-188(291)144(58-60-178(278)279)231-203(306)164-44-28-73-260(164)210(313)156(104-215(6,7)8)242-200(303)159(226-125(5)266)111-324-89-64-173(252)273)43-22-23-69-220-170(270)59-53-133-107-257(250-249-133)76-78-318-80-82-320-84-86-321-85-83-319-81-79-317-77-61-171(271)227-163-115-328-93-68-177(277)256-117-251-116-253(121-256)175(275)66-91-326-113-161(247-197(300)154(102-180(282)283)236-193(296)150(239-206(309)167-47-29-74-261(167)211(163)314)97-130-35-25-34-129-33-15-16-36-137(129)130)201(304)230-145(62-87-322-9)189(292)228-143(42-21-24-70-221-214(218)219)186(289)235-153(101-179(280)281)196(299)234-151(98-131-105-222-140-40-19-17-37-138(131)140)194(297)243-157(109-264)198(301)248-182(124(4)265)213(316)262-75-30-48-168(262)212(315)263-108-136(269)100-169(263)207(310)240-152(99-132-106-223-141-41-20-18-38-139(132)141)195(298)244-158(184(217)287)110-323-88-63-172(251)272/h12-20,25,31-38,40-41,49-52,54-57,105-107,122-124,136,142-169,182,222-223,264-265,267-269H,10-11,21-24,26-30,39,42-48,53,58-104,108-121H2,1-9H3,(H2,216,286)(H2,217,287)(H,220,270)(H,224,302)(H,225,293)(H,226,266)(H,227,271)(H,228,292)(H,229,294)(H,230,304)(H,231,306)(H,232,291)(H,233,305)(H,234,299)(H,235,289)(H,236,296)(H,237,308)(H,238,307)(H,239,309)(H,240,310)(H,241,288)(H,242,303)(H,243,297)(H,244,298)(H,245,290)(H,246,295)(H,247,300)(H,248,301)(H,278,279)(H,280,281)(H,282,283)(H,284,285)(H4,218,219,221)/t122-,123-,124+,136+,142-,143-,144-,145-,146+,147-,148-,149-,150-,151-,152-,153-,154+,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,182-/m0/s1

Standard InChI Key:  GTLNVSRQLUUNCK-UOVMZEQOSA-N

Associated Targets(Human)

TNFRSF9 Tbio Tumor necrosis factor receptor superfamily member 9 (13 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

CT26 (928 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 4707.50Molecular Weight (Monoisotopic): 4703.9890AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Upadhyaya P, Kristensson J, Lahdenranta J, Repash E, Ma J, Kublin J, Mudd GE, Luus L, Jeffrey P, Hurov K, McDonnell K, Keen N..  (2022)  Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology.,  65  (14.0): [PMID:35819182] [10.1021/acs.jmedchem.2c00505]

Source